Vericel Corp (NASDAQ:VCEL)
| Market Cap | $2.94B+45.3% |
| Revenue (ttm) | $324.17M+25.3% |
| Net Income | $33.31M+154.6% |
| EPS | $0.64+170.3% |
| Shares Out | 51.03M |
| PE Ratio | 87.15 |
| Forward PE | 60.86 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 582,315 |
| Open | $58.11 |
| Previous Close | $58.26 |
| Day's Range | $57.39 - $59.49 |
| 52-Week Range | $28.95 - $59.75 |
| Beta | 1.06 |
| Analysts | Buy |
| Price Target | $62.50(+8.66%) |
| Earnings Date | Feb 25, 2027 |
About VCEL
Vericel Corporation operates as a biopharmaceutical firm that has reached the commercialization phase, specializing in the research, development, production, and distribution of cell-based treatments. Its primary therapeutic areas are sports medicine and critical burn care across the United States. The company's product lineup includes MACI, an autologous cellularized scaffold employed for mending symptomatic, full-thickness cartilage damage in the knee, and Epicel, a permanent skin replacement designated as a humanitarian use device for treating deep-dermal or full-thickness burns in both adults and children. Additionally, Vericel is progressing NexoBrid, an orphan biological product currently in the registration phase, which aims to remove eschar from deep partial-thickness or full-thickness thermal burns in adults. Established in 1989 under its former name, Aastrom Biosciences, Inc., the company is headquartered in Cambridge, Massachusetts.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
3 firms rating VCEL in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Feb 25, 2027Earnings report
$VCEL stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in VCEL holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by VCEL's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
VCEL Estimated quarterly lobbying spending
Source: U.S. Senate LDA
VCEL Revenue by Segment
| Product sales, net | $85.37M | 96.61% |
| Nexobrid | $3.00M | 3.39% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New VCEL patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to VCEL from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in VCEL
| IJRiShares Core S&P Small-Cap ETF | $179.68M |
| IWMiShares Russell 2000 ETF | $78.72M |
| XBIState Street SPDR S&P Biotech ETF | $65.90M |
| VTIVanguard Morningstar Total Stock Market ETF | $51.84M |
| IWOiShares Russell 2000 Growth ETF | $28.42M |
| SPSMState Street SPDR Portfolio S&P 600 Small Cap ETF | $27.36M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from VCEL’s recent data — informational, not investment advice
What’s Behind the Score
News check: Analyst upgrade to $65 PT, rising earnings estimates, and Q3 earnings call signal positive momentum for VCEL.
Recent Insider Activity
Insider Score Trend Over Time
-39.0 since Aug 21Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
Frequently Asked Questions
ETFs that hold this stock
| PBE | Invesco Biotechnology & Genome ETF | 3.69% |
| FFTY | CapForce IBD 50 ETF | 2.05% |
| SBIO | ALPS Medical Breakthroughs ETF | 1.92% |
| PSCH | Invesco S&P SmallCap Health Care ETF | 1.60% |
| LFSC | F/M Emerald Life Sciences Innovation ETF | 1.46% |
| JSMD | Janus Henderson Small/Mid Cap Growth Alpha ETF | 1.37% |
| JSML | Janus Henderson Small Cap Growth Alpha ETF | 1.22% |
| CAFG | Pacer US Small Cap Cash Cows Growth Leaders ETF | 1.12% |
| LITL | Simplify Piper Sandler US Small-Cap PLUS Income ETF | 0.78% |
| XBI | State Street SPDR S&P Biotech ETF | 0.64% |
| AESG | Harbor AlphaEdge Small Cap Growth ETF | 0.60% |
| FYC | First Trust Small Cap Growth AlphaDEX Fund | 0.54% |
Weight is the stock’s share of each fund’s holdings.
